BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

444.76M

Vuru Grade

23.50/100

Current Price

$6.03
-0.01 (-0.17%)

Company Metrics

  • P/E 0
  • P/S 20.28
  • P/B 111.85
  • EPS -0.94
  • Cash ROIC -251.78%
  • Cash Ratio 0.80
  • Dividend 0 / 0%
  • Avg. Vol. 964,650.00
  • Shares 73.76M
  • Market Cap. 444.76M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Here's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July
Motley Fool - Aug 11, 2016
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company primarily focused on small-molecule drugs that block enzymes associated with disease development, leaped 27% in July, according to data from S&P Global Market ...
The BioCryst Pharmaceuticals, Inc. (BCRX) Raised to “Buy” at Zacks Investment ...
DailyQuint - 8 hours ago
Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning.
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Stock Technicals Hit Strength - CML News
To Buy Or Sell BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) On Latest Analyst ... - Fiscal Standard
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Quarterly EPS Set At $-0.21
Stock Observer - 15 hours ago
Zacks is famed for its evaluations that it carries out to get a price target of the establishments listed on the exchange. The firms take the financial report views and stock targets from top brokerages.
Hot Stock Overview: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
FactsReporter - Dec 12, 2016
Many analysts have provided their estimated foresights on BioCryst Pharmaceuticals, Inc. Earnings, with 8 analysts believing the company would generate an Average Estimate of $-0.22.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Approaching Earnings Date: What ... - The Voice Registrar
BioCryst Pharmaceuticals Inc. (BCRX) Soars 9.22% on December 26
Equities.com - Dec 26, 2016
BioCryst Pharmaceuticals Inc. (BCRX) had a good day on the market for Monday December 26 as shares jumped 9.22% to close at $6.99.
Stock's Stunning Activities: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
FactsReporter - Jan 17, 2017
BioCryst Pharmaceuticals, Inc. on 11/07/2016 reported its EPS as $-0.16 with the analysts projecting the EPS of the stock as $-0.24.
Biotech stocks for your portfolio: BioCryst Pharmaceuticals, Inc. (BCRX ... - The Independent Republic
BioCryst Pharmaceuticals, Inc. (BCRX) Downgraded by Zacks Investment Research ...
The Cerbat Gem - Jan 11, 2017
BioCryst Pharmaceuticals, Inc. logo Zacks Investment Research cut shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a buy rating to a hold rating in a research note released on Tuesday morning. According to Zacks, “BioCryst Pharmaceuticals, ...
Stock's Trend Analysis Report: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - TopChronicle
BioCryst Pharmaceuticals Inc. (BCRX) Soars 8.18% on January 04
Equities.com - Jan 4, 2017
BioCryst Pharmaceuticals Inc. (BCRX) had a good day on the market for Wednesday January 04 as shares jumped 8.18% to close at $6.88.
BioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Rating of "Buy" by ...
The Cerbat Gem - Dec 30, 2016
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has earned an average rating of “Buy” from the ten analysts that are presently covering the stock.
Analysts Set BioCryst Pharmaceuticals, Inc. (BCRX) Target Price at $7.50 - BBNS
Daily Sentiment Score Of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) At 0.31 - Stock Observer
BioCryst Pharmaceuticals, Inc. (BCRX) Downgraded by Zacks Investment Research
Sports Perspectives - Jan 13, 2017
Zacks Investment Research lowered shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a buy rating to a hold rating in a research report sent to investors on Tuesday.